N/A
Completed N=36
Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)
Source: ClinicalTrials.gov NCT01445873 ↗Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Jun 2012
Primary outcomePrimary: Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Mean Time to Therapy Augmentation — 2.2 months
Summary
The objectives of this study are to develop research methods and corresponding materials for a study of the effectiveness of sitaxentan sodium (Thelin) in "real-world" settings; to pilot test these methods at three study centers in Europe; and to refine and finalize research methods and corresponding materials for possible use in a follow-on, full-scale examination of the effectiveness of sitaxentan sodium (Thelin) in "real-world" settings.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Mean Time to Therapy Augmentation |
2.2 | — |
| PRIMARY Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Therapy Switching |
— | — |
| PRIMARY Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Therapy Discontinuation |
— | — |
| PRIMARY Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Therapy Duration |
6 | — |
| PRIMARY Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Numbers of Therapy-days Dispensed |
— | — |
| PRIMARY Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Daily Dosage |
100.0 | — |
| SECONDARY Use of Other Pulmonary Arterial Hypertension (PAH)-Related Medications |
83.3; 88.9; 22.2; 5.6; 44.4; 27.8 | — |
| SECONDARY Change From Baseline in World Health Organization (WHO) Functional Class of Pulmonary Hypertension |
0; 0; 0; 0; 0; 1 | — |
| SECONDARY Change From Baseline in Mean Right Atrial Pressure |
-1.3 | — |
| SECONDARY Change From Baseline in Mean Pulmonary Artery Pressure |
— | — |
| SECONDARY Change From Baseline in Pulmonary Capillary Wedge Pressure |
3.0 | — |
| SECONDARY Change From Baseline in Left Ventricular End Diastolic Pressure |
— | — |
| SECONDARY Change From Baseline in Pulmonary Vascular Resistance |
-214.3 | — |
| SECONDARY Change From Baseline in Cardiac Output |
0.4 | — |
| SECONDARY Change From Baseline in Tei Index |
-0.1 | — |
| SECONDARY Change From Baseline in Tricuspid Regurgitant Velocity |
-0.3 | — |
| SECONDARY Change From Baseline in the Total Distance Walked During 6 Minute Walk Test (6MWT) |
28.5 | — |
| SECONDARY Change From Baseline in Borg Dyspnoea Score |
4.9 | — |
| SECONDARY Change From Baseline in Percent of Predicted Peak VO2 |
3.5 | — |
| SECONDARY Pulmonary Arterial Hypertension (PAH) Severity and Functional Status: Time to Clinical Worsening |
2.8 | — |
| SECONDARY Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Mortality |
— | — |
| SECONDARY Number of Hospitalizations |
0.5 | — |
| SECONDARY Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Lung Transplantation |
— | — |
| SECONDARY Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Heart/Lung Transplantation |
— | — |
| SECONDARY Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Atrial Septostomy |
— | — |
Eligibility Criteria
Inclusion Criteria
- Idiopathic PAH, or PAH secondary to connective tissue disease
- Receipt of Thelin for treatment of PAH
- 6 months of follow-up (except in the event of death) subsequent to initial receipt of Thelin
- Minimum of one clinic visit documented in the medical record during the 6-month period subsequent to initial receipt of Thelin
Exclusion Criteria
- Participation in any investigational study of Thelin or any other medication for the treatment of PAH during the period beginning 6 months prior to initial receipt of Thelin and ending 6 months subsequent to such receipt
- Receipt of Thelin prior to January 11, 2005 (i.e., the date following the last day on which patients could be enrolled in double-blind treatment in STRIDE-1, STRIDE-2, and/or STRIDE-6); or
- Known contraindications to Thelin therapy (i.e., known hypersensitivity to sitaxsentan or any of its excipients; mild-to-severe hepatic impairment [Child-Pugh Class A-C]; elevated aminotransferases prior to initiation of treatment, defined as aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT] >3 times upper limit of normal [ULN]; concomitant use of cyclosporin A; lactation)
Data sourced from ClinicalTrials.gov (NCT01445873). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.